Table 1.
Participant Characteristics
| Characteristic | All Survivors (N=319) | High Symptom (N=51) | Low Symptom (N=268) | Controls (N=347) |
|---|---|---|---|---|
| Completed 12-month follow-up, n (%) | 235 (73.7) | 33 (64.7) | 202 (75.4) | 307 (88.5) |
| Completed 24-month follow-up, n (%) | 205 (64.3) | 29 (56.9) | 176 (65.7) | 254 (73.2) |
| Age, Mean (SD) Race, n (%) | 68.2 (6.1) | 67.5 (5.1) | 68.4 (6.3) | 67.8 (7.0) |
| Othera | 66 (20.7) | 13 (25.5) | 53 (19.8) | 73 (21.0) |
| Non-Hispanic White | 253 (79.3) | 38 (74.5) | 215 (80.2) | 273 (78.7) |
| Years of Education, Mean (SD) | 15.2 (2.2) | 14.9 (2.1) | 15.2 (2.2) | 15.4 (2.3) |
| WRAT-4 Standardized Score, Mean (SD) | 111.2 (15.4) | *107.0 (15.1) | 112.0 (15.4) | 111.8 (16.1) |
| Total Number of Comorbidities, Mean (SD) | 2.6 (1.9) | *3.2 (2.4) | 2.4 (1.8) | 2.4 (1.8) |
| APOE ε4 Carrier, n (%) | 57 (17.9) | 9 (17.6) | 48 (17.9) | 84 (24.2) |
| AJCC Stage, n (%) | ||||
| 0–1 | 213 (66.8) | *26 (51.0) | 187 (69.8) | n/a |
| 2–3 | 105 (32.9) | *24 (47.1) | 81 (30.2) | |
| Surgery, n (%) | ||||
| Lumpectomy | 177 (55.5) | 28 (54.9) | 149 (55.6) | |
| Mastectomy | 140 (43.9) | 23 (45.1) | 117 (43.7) | |
| Cancer Treatment Received, n (%) | ||||
| Hormonal only | 90 (28.2) | *21 (41.2) | 69 (25.7) | |
| Chemotherapy+/-Hormonal | 217 (68.0) | *30 (58.8) | 187 (69.8) | |
| Radiation Treatment, n (%) | 171 (53.6) | 27 (52.9) | 144 (53.7) | |
| Pre-treatment Symptom T-score, Mean (SD) | ||||
| Anxiety | 51.9 (11.6) | *70.4 (14.9) | 48.5 (6.5) | 48.2 (7.8) |
| Depression | 51.8 (11.6) | *73.7 (10.7) | 47.9 (6.0) | 48.3 (7.9) |
| Fatigue | 52.3 (12.2) | *70.7 (18.2) | 48.8 (6.1) | 47.8 (6.6) |
| Sleep Disturbance | 51.6 (10.5) | *61.8 (9.5) | 49.7 (9.5) | 48.5 (9.3) |
| Pain | 50.7 (10.4) | *60.4 (12.2) | 48.9 (8.9) | 49.2 (9.6) |
*
Significantly different from low symptom group at p<0.05. WRAT-4=Wide Range Achievement Test, 4th edition.
a
Other race includes Black, Hispanic, and American Indian/Alaska Native. Numbers may not add to 100% due to missing data.